Apollo Health Ventures is an Early Stage Investment Firm interested in accelerating breakthrough scientific discoveries to the clinic by building life science companies around new therapeutic technologies. Apollo Health Ventures focuses on assets with the potential to treat, prevent, or even reverse age-related diseases such as Alzheimer's, Heart Disease, Sarcopenia, Frailty, and Cancer, with the ultimate goal of increasing healthy human lifespan. Apollo invests in early stage companies, works with scientists and entrepreneurs to create new ventures, and engages in hypothesis-driven company building.
Location: Germany, Berlin
Employees: 11-50
Founded date: 2016
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 4
| Date | Name | Website | Total Raised | Location |
| 22.06.2026 | bionyra.com | $165M | France | |
| - | Samsara Th... | samsaratherapeutics.com | $3.2M | United Kin... |
| - | Cleara Bio... | clearabiotech.com | $2.5M | Netherland... |
| - | Aeovian Ph... | aeovian.com | $105M | United Sta... |
Mentions in press and media 13
| Date | Title | Description |
| 22.06.2026 | Bionyra Pharma Raises $165 Million Series A To Advance Biologics For Inflammatory Diseases | Bionyra Pharma announced its launch and an oversubscribed $165 million Series A financing round. The round was co-led by Jeito Capital and Sofinnova Partners. Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Heal... |
| 22.06.2026 | Bionyra Pharma Raises $165M in Series A Funding | Bionyra Pharma, a Paris, France- and Boston, MA-based clinical-stage biopharmaceutical company developing new biologics for immune-mediated inflammatory diseases, raised $165M in Series A funding. The round was led by Jeito Capital and Sofi... |
| 08.05.2025 | HAYA Therapeutics: Pioneering the Future of RNA-Guided Therapies | In the world of biotechnology, innovation is the lifeblood. HAYA Therapeutics has just secured a hefty $65 million in Series A funding, a financial boost that could change the landscape of chronic and age-related disease treatment. This fun... |
| 08.05.2025 | HAYA Therapeutics banks $65 million Series A funding | HAYA Therapeutics is a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases. The core of HAYA’s proprie... |
| 05.12.2024 | Refoxy Pharmaceuticals Secures €9.1 Million to Tackle Idiopathic Pulmonary Fibrosis | In the bustling world of biotechnology, where innovation meets necessity, Refoxy Pharmaceuticals has emerged as a beacon of hope. The Berlin-based company recently announced a significant funding milestone, raising €9.1 million in a seed ex... |
| 04.12.2024 | Refoxy Pharmaceuticals raises €9.1 million to progress its novel FOXO3 therapeutics for Idiopathic Pulmonary Fibrosis | Investment led by Boehringer Ingelheim Venture Fund, with the participation of new & existing investors, including Apollo Health Ventures, NRW.Venture, & HTGF. COLOGNE, GERMANY, December 4, 2024 /EINPresswire.com/ -- Refoxy Pharmace... |
| 14.10.2022 | Paul Scherrer Institute and Apollo Health Ventures launch Focal Biosciences | |
| 10.02.2022 | New US Laboratory and funding for HAYA Therapeutics | |
| 11.12.2021 | Apollo Health Ventures Closes Fund II, at $180M | Apollo Health Ventures, a Boston, MA and Berlin, Germany-based venture capital firm specialized in developing and investing in data-driven biotechnology and health tech ventures, closed its second venture fund at $180m. . Apollo Health Vent... |
| 01.12.2021 | Apollo Health Ventures Closes $180 Million Fund to Drive Breakthrough Innovations Combating Age-related Diseases | Apollo Health Ventures announces the final closing of its second venture fund to build a portfolio of data-driven biotechnology and healthtech ventures aimed at extending human healthspan. The oversubscribed Apollo Health Ventures Fund II s... |
Show more